Our finding that the PTP-defective Shp2CSDA suppresses EGFRL858R-induced lung adenocarcinoma in transgenic mice suggests that Shp2 PTP is a potential target for therapeutic development in EGFR-driven lung adenocarcinoma. This evidence concerns the gene EGFR and lung adenocarcinoma.